Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
Cancer Genetics Will Also Present a Corporate Overview on Thursday, October 19th
RUTHERFORD, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced it will be hosting a panel discussion focused on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” at this year's Dawson James Small Cap Growth Conference on October 18th in Jupiter, Florida. Panel participants will include Krishnan Nandabalan, Ph.D., President and CEO of InveniAI Corporation, Sundeep Bhan, co-founder and CEO of Prognos, George C. Carpenter IV, President and CEO of MYND Analytics, Inc., Evan Jones, Chairman and CEO of Opgen, Inc., and Karim Galil, MD, founder and CEO of Mendel.ai.
Hosted by Cancer Genetics’ President and CEO, Panna Sharma, the panelists will discuss how breakthrough Artificial Intelligence and Deep Learning Engines are now being used to transform virtually all aspects of healthcare, from clinical trial matching to drug discovery, and from selecting novel combination therapies to predicting patient outcomes.
These emerging technologies, combined with state of the art genomic and biomarker data, can accelerate the adoption of precision medicine and improve patient outcomes while lowering costs.
Panna Sharma will also provide an update on Cancer Genetics’ initiative around Big Data and Artificial Intelligence and how the Company is partnering with other leaders to use artificial intelligence to help revolutionize how patients are matched with clinical trials. With less than 5% of patients with cancer participating in clinical trials, according to the National Cancer Institute, advances in Artificial Intelligence and other developments in precision medicine could not only fundamentally transform cancer care, but more importantly cancer development. Cancer Genetics is among the first clinical diagnostic companies to be able to augment the oncologist's decision-making by continuously matching the patient’s data with emerging clinical trials.
In addition, Mr. Sharma will provide an overview of the Company's business on October 19th with a live presentation and will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.
3rd Annual Dawson James Small Cap Growth Conference – Cancer Genetics, Inc. Presentation
|Date:||Thursday, October 19, 2017|
|Time:||11:00 am Eastern Time|
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India, China and Australia. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow us:
FORWARD LOOKING STATEMENTS:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
INVESTOR RELATIONS CONTACT:
The Piacente Group, Inc.
Released October 12, 2017